SINGAPORE (July 14): Hyphens Pharma shares climbed 4.7% to 33.5 cents as at 11.58am on Tuesday following news that its patent for Ceradan Advanced has been granted in the UK on Monday evening.
The stock closed at 32 cents on the same day, prior to the announcement.
Ceradan Advanced is a patented next-generation emollient therapy for eczema-prone skin conditions. It is currently waiting for approval in 13 other countries including Singapore, Malaysia, China, and the US.
“The patent approval of Ceradan Advanced is an affirmation of our research‐based approach to product development. Patenting our Intellectual Property is strategic as it contributes towards the expansion of Ceradan Advanced’s branding,” says Lim See Wah, CEO of Hyphens Pharma.
